10:54 AM EDT, 09/27/2024 (MT Newswires) -- Lexaria Bioscience ( LEXX ) said Friday that an unnamed independent review board has approved the firm's human pilot study 3 to evaluate a DehydraTECH-processed version of glucagon-like peptide, or GLP-1, plus glucose-dependent insulinotropic peptide, or GIP, tirzepatide in an oral dose format.

The subject recruitment will start shortly and the first dosing is expected late next month and the final doses to take place in late November, the company added.

Lexaria said it will carry out the trial in up to 10 healthy participants and will evaluate a single injected dose of Zepbound over a seven-day period against seven days of daily oral dosing of DehydraTECH-processed Zepbound, according to the company.

Additionally, Lexaria said that the contract research organization it hired to evaluate various DehydraTECH-GLP-1 formulations and other treatments, has filed the required information for its own human research ethics committee review. The study is slated to dose its first patient this winter in Australia.

Price: 3.00, Change: +0.03, Percent Change: +1.01